

The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

Aurobindo Pharma USA Inc. has initiated a voluntary Drug Recall to the retail level for the product **Glycopyrrolate Tablets, USP 1 mg (NDC 13107-014-01) Batch 01422002A1, Expiry 12/2023, and Batch 01421078A3, Expiry 09/2023, 100 tablet bottles** from the USA market due to out of specification test result exceeding the allowable limits for unknown impurities at the initial time point for batch 01422002A1 and at the nine-month time point for batch 01421078A3.

Glycopyrrolate is a quaternary ammonium compound that contains the synthetic anticholinergic, glycopyrrolate. This product is for use as adjunctive therapy in the treatment of peptic ulcer. To date, Aurobindo Pharma USA, Inc. has not received any reports of adverse events related to this recall.

Aurobindo Pharma USA Inc. began shipping of batch 01421078A3 on 11/12/2021 and batch 01422002A1 on June 22, 2022.